Ductal carcinoma in situ associated with triple negative invasive breast cancer : Evidence for a precursor-product relationship

Journal of Clinical Pathology

Volumn 66, Issue 8, 2013, Pages 665-670

  Thike, Aye Aye ^a   Iqbal, Jabed ^a   Cheok, Poh Yian ^a   Tse, Gary Man Kit ^b   Tan, Puay Hoon ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

34BETA E12; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P63; SMOOTH MUSCLE ACTIN; STEM CELL FACTOR RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

BREAST CANCER; BREAST PATHOLOGY; IMMUNOHISTOCHEMISTRY;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM GRADING; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84880600038     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-201428     Document Type: Article

References (44)

1. Goldstein NS, Murphy T. Intraductal carcinoma associated with invasive carcinoma of the breast. A comparison of the two lesions with implications for intraductal carcinoma classification systems. Am J Clin Pathol 1996;106:312-18.
2. Leong AS, Sormunen RT, Vinyuvat S, et al. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. Am J Clin Pathol 2001;115:709-18.
3. Tamimi RM, Baer HJ, Marotti J, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008;10:R67.
4. Buerger H, Otterbach F, Simon R, et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 1999;189:521-6.
5. Lampejo OT, Barnes DM, Smith P, et al. Evaluation of infiltrating ductal carcinomas with a DCIS component: Correlation of the histologic type of the in situ component with grade of the infiltrating component. Semin Diagn Pathol 1994;11:215-22.
6. O'Connell P, Pekkel V, Fuqua SA, et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998;90:697-703.
7. Lakhani SR, Chaggar R, Davies S, et al. Genetic alterations in 'normal' luminal and myoepithelial cells of the breast. J Pathol 1999;189:496-503.
8. Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 1999;187:272-8.
9. Hwang ES, DeVries S, Chew KL, et al. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res 2004;10:5160-7.
10. Erhardt K, Auer GU. Mammary carcinoma. Comparison of nuclear DNA content from in situ and infiltrative components. Anal Quant Cytol Histol 1987;9:263-7.
11. Mommers EC, Leonhart AM, Falix F, et al. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J Pathol 2001;194:327-33.
12. Gupta SK, Douglas-Jones AG, Fenn N, et al. The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ). Cancer 1997;80:1740-5.
13. Heaphy CM, Bisoffi M, Joste NE, et al. Genomic instability demonstrates similarity between DCIS and invasive carcinomas. Breast Cancer Res Treat 2009;117:17-24.
14. Ishikawa Y, Horiguchi J, Toya H, et al. Triple negative breast cancer: Histological subtypes and immunohistochemical and clinicopathological features. Cancer Sci 2011;102:656-62.
15. Thike AA, Cheok PY, Jara-Lazaro AR, et al. Triple-negative breast cancer: Clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 2010;23:123-33.
16. Thike AA, Iqbal J, Cheok PY, et al. Triple negative breast cancer: Outcome correlation with immunohistochemical detection of basal markers. Am J Surg Pathol 2010;34:956-64.
17. Zhou W, Jirstrom K, Johansson C, et al. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: A population-based cohort study. BMC Cancer 2010;10:653.
18. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: A possible precursor to invasive basal-like breast cancer. Mod Pathol 2006;19:617-21.
19. Dabbs DJ, Chivukula M, Carter G, et al. Basal phenotype of ductal carcinoma in situ: Recognition and immunohistologic profile. Mod Pathol 2006;19:1506-11.
20. Hannemann J, Velds A, Halfwerk JB, et al. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 2006;8:R61.
21. Livasy CA, Perou CM, Karaca G, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007;38:197-204.
22. Clark SE, Warwick J, Carpenter R, et al. Molecular subtyping of DCIS: Heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer 2011;104:120-7.
23. Tan PH, Goh BB, Chiang G, et al. Correlation of nuclear morphometry with pathologic parameters in ductal carcinoma in situ of the breast. Mod Pathol 2001;14:937-41.
24. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
25. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
26. Kuerer HM, Albarracin CT, Yang WT, et al. Ductal carcinoma in situ: State of the science and roadmap to advance the field. J Clin Oncol 2009;27:279-88.
27. Allred DC, Wu Y, Mao S, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 2008;14:370-8.
28. Hu M, Yao J, Carroll DK, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008;13:394-406.
29. Sharma M, Beck AH, Webster JA, et al. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast Cancer Res Treat 2010;123:397-404.
30. Espina V, Liotta LA. What is the malignant nature of human ductal carcinoma in situ? Nat Rev Cancer 2011;11:68-75.
31. Roses RE, Paulson EC, Sharma A, et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18:1386-9.
32. Schnitt SJ. The transition from ductal carcinoma in situ to invasive breast cancer: The other side of the coin. Breast Cancer Res 2009;11:101.
33. Hu M, Peluffo G, Chen H, et al. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci U S A 2009;106:3372-7.
34. Castro NP, Osorio CA, Torres C, et al. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res 2008;10:R87.
35. Lee S, Stewart S, Nagtegaal I, et al. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res 2012;72:4574-86.
36. Subramanian B, Axelrod DE. Progression of heterogeneous breast tumors. J Theor Biol 2001;210:107-19.
37. Poller DN, Galea M, Pearson D, et al. Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma. Breast Cancer Res Treat 1991;20:3-10.
38. Bose S, Lesser ML, Norton L, et al. Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med 1996;120:81-5.
39. Bobrow LG, Happerfield LC, Gregory WM, et al. Ductal carcinoma in situ: Assessment of necrosis and nuclear morphology and their association with biological markers. J Pathol 1995;176:333-41.
40. Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992;23:974-9.
41. Barnes DM, Bartkova J, Camplejohn RS, et al. Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 1992;28:644-8.
42. Sontag L, Axelrod DE. Evaluation of pathways for progression of heterogeneous breast tumors. J Theor Biol 2005;232:179-89.
43. Larson PS, de las Morenas A, Bennett SR, et al. Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas. Am J Pathol 2002;161:283-90.
44. Rakha EA, Reis-Filho JS, Ellis IO: Basal-like breast cancer: A critical review. J Clin Oncol 2008;26:2568-81.